| Similar Articles |
|---|
 |
The Motley Fool
July 30, 2007
Brian Orelli |
Another Blow to Gene Therapy The FDA shuts down a clinical trial, tripping up Targeted Genetics and possibly its competitors. A subject in the trial of their gene therapy arthritis medication died shortly after taking the drug.   |
BusinessWeek
April 30, 2007
Catherine Arnst |
Teaching The Body To Fix Itself Cancer vaccines still in trial stages may be able to prolong life with few side effects, but the FDA has yet to be convinced. |
HHMI Bulletin
Aug 2011 |
Seeing is Believing Today, researchers are finding clever ways to deliver long-lasting, healthy genes without triggering a serious immune response. |
BusinessWeek
June 13, 2005
Catherine Arnst |
Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins. |
BusinessWeek
April 22, 2010
Rob Waters |
Gene Therapy Takes a Turn for the Better Researchers and investors are heartened by advances in gene therapy. Analysts say revenues are still several years off, however. |
BusinessWeek
May 27, 2010
Pettypiece & Gibson |
Training the Immune System to Fight Cancer Bristol-Myers' new melanoma drug may be a "game changer." |
HHMI Bulletin
Nov 2010 |
Fusion genes that drive solid tumors are a new target for cancer therapies The success of Gleevec and related drugs has inspired researchers to step up their hunt for the molecular defects underlying other cancers. |
BusinessWeek
August 26, 2010
Tom Randall |
Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer. |
BusinessWeek
July 17, 2006
Bruce Einhorn |
A Key New Ally In The Cancer War China and its Western trade partners are fighting together on at least one front: the war on cancer. |
The Motley Fool
June 4, 2007
Brian Lawler |
Is Introgen Stringing Investors Along? Investors, this is one development-stage drugmaker not to own. |
BusinessWeek
February 12, 2007
Bruce Einhorn |
Stem-Cell Refugees Americans are flocking to China for therapy. |
BusinessWeek
February 10, 2011
Rob Waters |
Sangamo's Bet Against AIDS: Gene Therapy Sangamo's stock has more than doubled since July 6, when the company, with no products on the market, reported success of its gene therapy approach in mice in the journal Nature Biotechnology. |
Pharmaceutical Executive
July 1, 2011
Dickmeyer & Rosenbeck |
From Rut to Racetrack Can the pharmaceutical industry deliver on its objective to make cancer a curable, chronic condition? |
Fast Company
December 2009
Elizabeth Svoboda |
Biotechs Look Overseas to Launch a Stem-Cell Revolution According to one small biotech, the best way to launch a stem-cell revolution is to do it overseas. |
The Motley Fool
August 2, 2010
Brian Orelli |
Back in Love With Geron Investors' love / hate relationship with Geron is back in the worship phase, with the stem cells company up 17% on Friday and nearly an additional 10% or so today. |
BusinessWeek
June 21, 2004
Catherine Arnst |
Cancer Superdrugs, Costly Side Effects New therapies are extending lives, but the prices could weigh down the nation. Oncologists, pharmaceutical companies, and the government will have to focus on the best way to lower prices for these drugs. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Cancer: On Target Once More Over the past year or two, a handful of Phase III failures, including megablockbusters like Avastin and Sutent in trials for all kinds of common tumors, indicate that targeted therapy is generally a blunt instrument. |
HHMI Bulletin
Nov 2011
Renee Twombly |
A New Take on Retinoblastoma Basic research findings upend old thoughts on this childhood tumor. |
Salon.com
June 1, 2000
Tabitha M. Powledge |
Gene therapy R.I.P.? When the country's biggest gene therapy institute was ordered to stop testing on humans last week, the action marked the end of an era fraught with dubious claims to success and a mess of unreported adverse effects. |
The Motley Fool
June 17, 2010
Luke Timmerman |
Oncothyreon's Cancer Vaccine Back in the Saddle as Merck KGaA Re-Starts Clinical Trials The German-based Merck got clearance from the FDA and local ethics review boards to resume two of three large pivotal trials. |
Scientific American
March 2009
Elaine Schattner |
A Chip against Cancer: Microfluidics Scrutinizes T Cells With just a blood sample, a device could determine whether cancer is about to spread or monitor the progress of treatment |
BusinessWeek
June 6, 2005
Catherine Arnst |
Better Odds Against Breast Cancer New treatments for breast cancer are more effective, and easier to live with |
The Motley Fool
November 2, 2004
Charly Travers |
Biotech's 5-Baggers: Part 3 Year after year, the hottest biotech companies with investors are those with drugs in development for the treatment of cancer. |
BusinessWeek
September 5, 2005
Michael Arndt |
Fine-Tuning the Attack on Breast Cancer Genentech's Herceptin, the first drug approved for a specific group, helps patients who are genetically susceptible to a virulent form of the disease. |
BusinessWeek
April 12, 2004
John Carey |
Gene-Based Therapy: Back To The Couch Recent setbacks show (again) that biotech needs more patience and less ballyhoo |
Pharmaceutical Executive
February 1, 2013
William Looney |
Pathways to Progress Cancer is increasingly understood as a collection of rare and mostly treatable conditions rather than the impregnable, monolith portrayed in popular culture. Industry experts review current and pending efforts to turn great science into good practice. |
BusinessWeek
February 12, 2007
Burrows & Saminather |
Precision-Guided Cancer Weapons Innovations in radiation therapy are reducing "collateral damage" and saving lives. |
Chemistry World
March 4, 2011
Elinor Richards |
Laser treatment for late-stage cancer Scientists from China, the US and Peru claim to have successfully treated late-stage breast cancer patients using laser immunotherapy to stimulate patients' own immune systems to fight the cancer. |
BusinessWeek
April 4, 2005
Arlene Weintraub |
Biotech's Fountain Of Youth A review of the book "More Than Human: Embracing the Promise of Biological Enhancement." The book by Ramez Naam provides a look at biotech's role in the future of medicine. |
Pharmaceutical Executive
April 1, 2006
Joanna Breitstein |
HBA Woman of the Year: Susan Desmond-Hellman There are people who hope cancer, one day, will become a manageable disease. Then there are those who know it. Meet Susan Desmond-Hellmann. |
Reason
Aug/Sep 2007
Kerry Howley |
Dying for Lifesaving Drugs Will desperate patients destroy the pharmaceutical system that produces tomorrow's treatments? |
Pharmaceutical Executive
June 1, 2007 |
Thoughtleader: Stephen Sherwin, Cell Genesys Cell Genesys has been able to raise enough capital to gamble on what it CEO believes could be the future's most promising therapies, including gene activation, immunotherapy, and oncolytic virus therapy. |
Managed Care
June 2007
Thomas Morrow |
Dendritic Cell Vaccine Hits FDA Roadblock Questions about study design and analysis prompted the FDA to postpone action on Provenge, a treatment for advanced prostate cancer. |
HHMI Bulletin
Aug 2011
Richard Saltus |
T-Cell Booster Kits A bioengineer remodels cell surfaces to prod the immune system. |
Chemistry World
July 2010
Hayley Birch |
Special Report: Health breakthroughs of the decade New discoveries have been made with cancer vaccines, genomics, statin drugs, allosteric modulators, and RNA interference during the last decade. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
May 8, 2009
Brian Orelli |
Investing Against Breast Cancer Many companies are interested in both a cure and a large lucrative market. Which are the best investments now in this sector? |
Scientific American
September 2009
Melinda Wenner |
Gene therapy: An Interview with an Unfortunate Pioneer Lessons learned by James M. Wilson, the scientist behind the first gene therapy death |
BusinessWeek
May 9, 2005
Catherine Arnst |
Genentech's Lessons For Big Pharma The biotech company focuses on science -- not marketing, acquisitions, or patents. |
The Motley Fool
May 7, 2007
Brian Orelli |
Introgen's Still Standing -- for Now With a lack of products, the biotech's burn rate is a key factor for investors to figure out its chance of survival. |
American Family Physician
February 1, 2004 |
Penile Cancer What is cancer?... How does my doctor check for cancer?... How is penile cancer treated? |
BusinessWeek
February 12, 2007
Nichola Saminather |
Radiation Therapy: New Rays Of Hope More than two-thirds of all cancer patients in the U.S. receive radiation treatments as part of their hospital care. New technology could greatly improve the prognosis. |
BusinessWeek
March 8, 2004
Arlene Weintraub |
And When ImClone's Drug Doesn't Work... Physicians have greeted ImClone Systems Inc.'s (IMCL ) cancer drug, Erbitux, with a mixture of glee and grim realism. The drug dramatically shrinks colon tumors in some patients. But in others, it has little effect -- and no one knows why. |
Pharmaceutical Executive
February 1, 2007
Bradley Thompson |
Virus as Viable Drug Coincidence or phenomena? The reovirus is Mother Nature's own cancer-killer. |
BusinessWeek
March 28, 2005
Timothy J. Mullaney |
Saving Lives Shouldn't Be This Hard The health-care system doesn't give patients the tools or the support they need to make confident decisions about choosing doctors, treatments, or hospitals. |
Scientific American
May 2009
Christine Soares |
Cancer Clues from Embryonic Development Rethinking cancer by seeing tumors as a cellular pregnancy. |
BusinessWeek
September 5, 2005
Capell & Arndt |
Drugs Get Smart Future medicines will more effectively target what ails you by tailoring treatment to your specific genetic profile. Personalized medicine will also help prevent another Vioxx. |
Managed Care
March 2007
Martin Sipkoff |
Managing Cancer Treatment Begins Before Diagnosis Health plans are increasingly involved in promoting the lifestyle changes that help their members avoid cancer, and are increasingly involved in clinical trials if prevention fails. |
Managed Care
August 2007
Thomas Morrow |
Gene Expression Microarray Improves Prediction of Breast Cancer Outcomes Flash-frozen samples of surgically removed breast cancer tissue are the key to measuring a patient's risk of metastasis. |
Fast Company
March 2006
Ramez Naam |
The Body: Bulletproof Gene therapy is on its way - and it's coming fast. |
